Under the EUA, regdanvimab is indicated for the treatment of confirmed Covid-19 in adult patients that do not require supplemental oxygen and who are at high risk for progressing to severe Covid-19.
Regdanvimab 60 mg
0-17 Years Old
The safety and efficacy of regdanvimab in pediatric patients have not yet been established. No data are available.
18 Years Old and Above
The recommended dosage of regdanvimab is a single intravenous (IV) infusion of 40 mg/kg. Treatment should be initiated as soon as possible after diagnosis, and not later than 7 days after the onset of symptoms.
65 Years Old and Above
No dose adjustment of regdanvimab is required in elderly patients.